Dr. Brent Martin Hjermstad, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Not Enrolled in Medicare Practice Location: 7370 N Old Cornfield Ln, Prescott, AZ 86305 Phone: 509-993-1374 Fax: 928-212-3945 |
Michael Anthony Arroyo, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 1003 Willow Creek Rd, Prescott, AZ 86301 Phone: 480-985-1093 Fax: 480-985-0468 |
Monty A Hawkins, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 1003 Willow Creek Rd, Prescott, AZ 86301 Phone: 480-985-1093 Fax: 480-296-7665 |
Roel Angel Gallo Jr., MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 1003 Willow Creek Rd, Prescott, AZ 86301 Phone: 480-985-1093 Fax: 480-985-0468 |
Dr. Philip Earl Keen, M.D. Pathology - Forensic Pathology Medicare: Not Enrolled in Medicare Practice Location: 980 Division St, Prescott, AZ 86301 Phone: 928-771-3163 Fax: 928-771-3105 |
Dr. Karen Marie Johnson, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Not Enrolled in Medicare Practice Location: 1003 Willow Creek Rd, Prescott, AZ 86301 Phone: 928-771-5761 Fax: 928-771-5175 |
News Archive
Current training and assessment for curbing common pitfalls in medicines prescribing for children is inadequate, suggests research published ahead of print in Archives of Disease in Childhood.
The heart of the Patient Protection and Affordable Care Act is the requirement that every American purchase health insurance or pay a penalty. Justice Anthony Kennedy-;widely considered the "swing vote" on cases that divide the Supreme Court evenly along ideological lines-;raised concerns on Tuesday that this individual mandate "changes the relationship of the federal government to the individual in the very fundamental way."
Hospira announced today that the EC has approved Nivestimâ„¢ (filgrastim) for the prevention of FN, the most serious haematological toxicity that occurs as a result of cancer chemotherapy. Nivestim now has marketing authorisation in all EU member states. Nivestim is expected to reduce the cost of neutropenia treatment.
Biogen Idec today issued the following statement regarding the United States (U.S.) Food and Drug Administration (FDA) approval of AMPYRAâ„¢ (dalfampridine) to improve walking in patients with multiple sclerosis (MS).
› Verified 6 days ago